[Molecular pathogenesis and treatment of chronic lymphocytic leukemia]

Chronic lymphocytic leukemia (CLL) is a rare type of lymphoid malignancy among Japanese. Its clinical course is indolent, and the prognosis is good. The two types of CLL based on the mutation status of the IgH gene V segment have been documented in the literature. Then, the del (17p)/TP53 subtype is emphasized, and the treatment strategy for the three subtypes differs. Recent knowledge on molecular pathogenesis facilitated the usage of Bruton's tyrosine kinase (BTK) and BCL2 inhibitors for the treatment of CLL. A better response can be obtained with the use of these novel agents, resulting in a higher rate of negativity for measurable residual disease (MRD). The treatment strategy based on MRD negativity and the treatment outcomes of CLL will improve in future.